GSK 3036656

Drug Profile

GSK 3036656

Alternative Names: GSK 3036656; GSK656

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anacor Pharmaceuticals
  • Class Antituberculars; Organic boron compounds; Small molecules
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Tuberculosis

Most Recent Events

  • 22 Jun 2018 GlaxoSmithKline plans a phase II trial for Tuberculosis in September 2018 (NCT03557281)
  • 04 Aug 2017 GlaxoSmithKline completes a phase I trial in Healthy volunteers in the United Kingdom (NCT03075410)
  • 02 Apr 2017 Phase-I clinical trials in Tuberculosis (In volunteers) in United Kingdom (PO) (NCT03075410)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top